Private Markets, Angel and Secondary Investing, Sacra

Sacra

Private Markets, Angel and Secondary Investing

Bringing transparency to private markets so investors, founders, and employees can build on conviction. Sacra delivers deeply researched insights on the private companies shaping tomorrow's markets. By surfacing the data, context, and operator perspective that are missing from private markets today, we help secondary buyers and sellers price equity accurately and unlock liquidity for the people building these businesses.

Private Capital Markets

<ul><li>Telehealth usage grew 38x worldwide in the first year of COVID—as European national health services raced to set up telehealth-friendly reimbursement structures, Kry emerged as one of the top digital healthcare providers in Europe, growing 124% from $38M revenue in 2019 to $85M in 2020 and then 92% to $164M in 2021.</li><li>With barriers to entry lowered and competitors flooding into telehealth during the pandemic, the market took a bearish sentiment post-COVID, with Teladoc (NYSE: TDOC) falling by 70% ($294 to $89 per share), Amwell (NYSE: AMWL) falling nearly 86% ($35 to $5 per share), and Hims (NYSE: HIMS) falling 75% (from $24 to under $6 per share).</li><li>Like the locally forged resistance faced by Vikings in their raids across Europe, Kry faces regional threats from established and well-capitalized players such as Doctolib ($815M raised) in France, Ada Health ($189.5M raised) in Germany, Babylon Health ($1.1B revenue in 2022) in the UK, and DocPlanner ($140.5M raised) in Poland.</li></ul>

Telehealth usage grew 38x worldwide in the first year of COVID—as European national health services raced to set up telehealth-friendly reimbursement structures, Kry emerged as one of the top digital healthcare providers in Europe, growing 124% from $38M revenue in 2019 to $85M in 2020 and then 92% to $164M in 2021.With barriers to entry lowered and competitors flooding into telehealth during the pandemic, the market took a bearish sentiment post-COVID, with Teladoc (NYSE: TDOC) falling by 70% ($294 to $89 per share), Amwell (NYSE: AMWL) falling nearly 86% ($35 to $5 per share), and Hims (NYSE: HIMS) falling 75% (from $24 to under $6 per share).Like the locally forged resistance faced by Vikings in their raids across Europe, Kry faces regional threats from established and well-capitalized players such as Doctolib ($815M raised) in France, Ada Health ($189.5M raised) in Germany, Babylon Health ($1.1B revenue in 2022) in the UK, and DocPlanner ($140.5M raised) in Poland.

<ul><li>Roman (now Ro, valued at $7B) and Hims (NYSE: HIMS) launched in 2017 to tap into the $4B ED market, using telehealth to do an end-around the stigmatized clinic visit.</li><li>With the wide onset of COVID in April 2020, telehealth consultations exploded to 78x of Feb 2020 levels, leading Ro’s valuation to grow 10x to $5B and precipitating Hims’s $1.6B IPO.</li><li>But COVID giveth and COVID taketh away—Ro’s yearly revenue growth dropped to an estimated 30% in 2021, and Hims is expected to grow by 50% in 2022, its lowest annual growth thus far.</li></ul>

Roman (now Ro, valued at $7B) and Hims (NYSE: HIMS) launched in 2017 to tap into the $4B ED market, using telehealth to do an end-around the stigmatized clinic visit.With the wide onset of COVID in April 2020, telehealth consultations exploded to 78x of Feb 2020 levels, leading Ro’s valuation to grow 10x to $5B and precipitating Hims’s $1.6B IPO.But COVID giveth and COVID taketh away—Ro’s yearly revenue growth dropped to an estimated 30% in 2021, and Hims is expected to grow by 50% in 2022, its lowest annual growth thus far.

<ul><li>Ro has shown significant revenue growth over the past year.</li><li>The company's competitive positioning remains strong in the market.</li><li>Future projections indicate continued expansion in the next fiscal year.</li></ul>

Ro has shown significant revenue growth over the past year.The company's competitive positioning remains strong in the market.Future projections indicate continued expansion in the next fiscal year.

<ul><li>Where we see Pawp evolving over the next few years is in really owning what we define as pet care—which not only encompasses vet care and the medical aspects of your pet&#39;s health, but also their overall wellbeing.</li><li>So far, we&#39;ve facilitated more than 100,000 consultations online in a year and a half, and deflected roughly $10 million worth of unnecessary vet visits.</li><li>We&#39;re leveraging partnerships to help distribute Pawp <em>en masse</em>—essentially providing pet parents everywhere access to affordable pet care.</li></ul>

Where we see Pawp evolving over the next few years is in really owning what we define as pet care—which not only encompasses vet care and the medical aspects of your pet&#39;s health, but also their overall wellbeing.So far, we&#39;ve facilitated more than 100,000 consultations online in a year and a half, and deflected roughly $10 million worth of unnecessary vet visits.We&#39;re leveraging partnerships to help distribute Pawp en masse—essentially providing pet parents everywhere access to affordable pet care.

Marc Atiyeh, CEO Of Pawp, On Building Telehealth For Pets

United States

Telehealth marketplace for online doctor visits and prescription delivery for men’s health

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ro (RO US)

Sweden’s $215M/year Telehealth Giant

TL;DR: Kry has grown into one of the top telehealth players in Europe at an estimated $215M in yearly revenue—now, armed with an AI chatbot for...

Sacra

Ro And The Telehealth Capital Cycle

D2C telehealth companies have come a long way from hocking generic Viagra, but the twin speed bumps of lofty valuations and the post-COVID reset...

Sacra

Ro Revenue, Growth And Comps

Sacra model for Ro's revenue, comps, and growth rate.

Sacra

Marc Atiyeh, CEO Of Pawp, On Building Telehealth For Pets

Sacra interview with Marc Atiyeh, CEO and co-founder of Pawp.

Sacra

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)